Efficacy of intermittent empagliflozin supplementation on dietary self‐management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24‐week randomized controlled trial

Aims To explore the effects of intermittent use of empagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on dietary self‐management and glycaemic control in patients with inadequately controlled type 2 diabetes. Materials and methods We conducted a prospective, randomized, open‐label, blinded‐...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-02, Vol.21 (2), p.303-311
Main Authors: Yoshikawa, Fukumi, Kumashiro, Naoki, Shigiyama, Fumika, Uchino, Hiroshi, Ando, Yasuyo, Yoshino, Hiroshi, Miyagi, Masahiko, Ikehara, Kayoko, Hirose, Takahisa
Format: Article
Language:English
Subjects:
Antidiabetics
Body weight
Body weight loss
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Dietary supplements
empagliflozin
Energy intake
Evidence-based medicine
Food intake
Glucose transporter
Hemoglobin
intermittent use
Management
Patients
Quality of life
self‐management
Sodium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To explore the effects of intermittent use of empagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on dietary self‐management and glycaemic control in patients with inadequately controlled type 2 diabetes. Materials and methods We conducted a prospective, randomized, open‐label, blinded‐endpoint, parallel‐group, comparative clinical trial of 50 patients with type 2 diabetes, treated with no more than three oral antidiabetic drugs (glycated haemoglobin [HbA1c] ≥52 mmol/mol but
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13524